Morgan Group Holding Co. (MGHL)
OTC PINK OTC PINK Primary 
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
According to JP Morgan, U.S. large-cap biopharma stocks have underperformed the broader market for two consecutive years, with mixed sentiment shaping investor outlook for 2025.
Why Morgan Stanley's Wealth Management Focus Makes It A Standout
Morgan Stanley's wealth management division achieved steady growth, contributing $6.6 billion in Q2 2024, providing stability amid volatile investment banking and trading revenues. The company returned $1.59 billion to shareholders in Q3 2024 through dividends, showcasing a strong commitment to shareholder value and confidence in long-term growth. Revenue fluctuated over the last year, peaking at $26.3 billion in Q1 2024, driven by a 15% surge in fixed-income trading activity.
Morgan Stanley: Some Of The Preferred Shares Still Yield 7%
Morgan Stanley's strong Q3 performance saw a 17% non-interest revenue increase and a 37% rise in net income attributable to common shareholders. The Series E preferred shares offer a fixed 7.125% dividend, but there's a risk of the bank calling them due to falling interest rates. A long position in these preferred shares hinges on Morgan Stanley not calling them soon. Buying close to $25 mitigates call risk.
Kinder Morgan Adds Another $1.4 Billion Project to Fuel Its More Than 4%-Yielding Dividend
Kinder Morgan (KMI 2.33%) pays its investors well. At its current share price, the natural gas pipeline giant's dividend yields 4.3% -- several times higher than the S&P 500 's 1.2% yield.
Kinder Morgan Advances $1.4B Mississippi Pipeline Project
KMI moves forward with its $1.4B Mississippi Crossing Project, aiming to add 1.5 Bcf/d gas capacity across 206 miles of pipeline in the Southeast U.S. by November 2028.
Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025
NEWARK, CA / ACCESSWIRE / December 19, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D.
What's Happening With Morgan Stanley Stock?
Morgan Stanley's stock (NYSE: MS) gained about 42% year-to-date. This compares to rival Goldman Sachs stock, which has seen its stock gain about 55% year-to-date.
Morgan Stanley Collaborates With Wise to Enhance Payment Capabilities
MS joins forces with Wise to enhance its foreign exchange settlement capabilities, boost its existing product suite and offer fast-paced services to corporate clients.
Morgan Stanley or Goldman: Which Stock to Keep an Eye on in 2025?
MS and GS are well-poised to gain from the revival of global M&As. Read on to know whether to bet on these stocks now or wait.
Nvidia's stock is very attractive at this level, says Morgan Stanley's Joseph Moore
Joseph Moore, Morgan Stanley semiconductor analyst, joins 'Squawk Box' to discuss Nvidia's recent stock slide, what the fair value of the company is, and more.
3 Stocks J.P. Morgan Just Upgraded and Why They're Bullish
Whenever analysts from Wall Street's biggest banks decide to come together to boost a particular group of stocks, retail investors do well to watch the trends, attempt to reverse engineer their views and opinions, and, more importantly, where they stem from. Confident analysts often land on a bullish or bearish view of a particular industry, where select stocks will gain more market attention.
Morgan Stanley Taps Wise Platform to Accelerate Cross-Border Settlements
Morgan Stanley will offer its clients high-speed cross-border settlements through Wise Platform. The investment bank tapped this solution from Wise, a global technology focused on money movement, to facilitate foreign exchange international settlement for its corporate and institutional clients, the companies said in a Tuesday (Dec. 17) press release.
